Beam Therapeutics Inc. BEAM announced that the FDA has cleared the investigational new drug (IND) application to begin ...

Prime Medicine, Inc. announced the launch of a preclinical program targeting alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting lung and liver function, utilizing their ...

Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...

Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

aimed at treating Alpha-1 Antitrypsin Deficiency (AATD), with interim results expected in the second half of 2025. The FDA has granted KRRO-110 Orphan Drug Designation, offering development ...

Mereo BioPharma (NASDAQ:MREO) traded higher on Thursday after J.P. Morgan launched its coverage with an overweight ...

Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...

Shares of Prime Medicine ( PRME 13.07%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.